20Oct 2022
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11

Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11

In the SUSTAIN 11 clinical trial, glucagon‐like peptide‐1 receptor agonist once‐weekly semaglutide was associated with improvements in glycated haemoglobin (HbA1c) and body weight versus insulin aspart in people with type 2 diabetes with inadequate glycaemic control on basal insulin. Therefore, the present study aimed to evaluate the long‐term cost‐effectiveness of once‐weekly semaglutide 1 mg versus insulin aspart in the UK. The study's findings indicated that based on a willingness‐to‐pay threshold of GBP 20,000 per QALY, once‐weekly semaglutide 1 mg was projected to be highly cost‐effective versus insulin aspart for the treatment of type 2 diabetes in the UK.

  • #endo-diabetology

Like

Save

Share